P19.01 RATIONALE-303 Phase 3 Tislelizumab vs Docetaxel in Previously Treated Advanced NSCLC: China Subgroup Analysis
2021
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
Old Web
English
Sign In
Email Address
acemap@cs.sjtu.edu.cn
- CCF Conference Analysis
- Map Galaxy
- Academic Report
- What's New
© Copyright 2015-2020 Acemap, Inc. Shanghai Jiao Tong University.